I just received an email question about whether multiple myeloma survivors should be eating asparagus. So I referred back to a column I wrote a year ago about it. I was surprised and pleased to note that 3,236 people had viewed that post. Pretty cool! I get too busy to keep track of such things. Maybe I should do some checking to try and find MMB’s most oft-read post some rainy day. Don’t hold your breath–aren’t a lot of those down here in sunny Florida!
Here’s a link to Danny’s well-reasoned explanation as to why it is probably a good idea for us to limit our asparagus consumption:
This got me thinking. I remember giving-up glucosamine supplements that I was taking for my ache knees based on Danny’s advice, too. Here’s a link back to that information:
Only 835 readers have viewed that one so far. Guess there are a lot more of us that want to eat asparagus than take glucosamine!
Did any of you happen to read Steve’s insightful follow-up comment to yesterday’s update about Dr. Bradner and JQ1?
Like you Pat, I too tend to be a bit cautious before proclaiming “Eureka”…I mean until a potential drug gets to a Phase 2 clinical trial it’s kinda hard to get overly excited.
And while you and I and most of the MM community debate the potential ROI on a molecule like JQ1 on a level we can understand, others, more knowledgeable of and insightful to the pharma industry debate it at a WHOLE nutha’ level…check this out:
Click-on the link Steve passed-along and you will soon discover that author Derek Lowe stirred-up a bundle of conflicting feelings about Dr. Bradner and JQ1.
Apparently, another team of scientists discovered the molecule’s possible applications around the same time that Bradner’s team did. This is a must read for any Bradner/JQ1 fan. But I warn you; it won’t be easy for supporters to see.
Man! If any of you thought I was overly skeptical/critical of the good doctor, you have got to read this. There are some haters out there. But also some insightful analysis by–as Steve so aptly states–“others, more knowledgeable of and insightful to the pharma industry debate it at a WHOLE nutha’ level…”
Mr. Bradner has already won me over. My interest was reading what a bunch of scholarly science nerds (I write that with love!) have to say about the process and potential for JQ1 to ever get to market.
One important thing to note: Lowe is quick to point-out that:
“JQ1 is not a drug, nor is it ever likely to become a drug. It has inspired research programs to find drugs, but they likely won’t look much (or anything) like JQ1, and they’ll do different things (for one, they’ll almost surely be more selective). In fact, chasing after that sort of selectivity is one of the things that Bradner’s own research group appears to be doing – and quite rightly – while his employer (Dana-Farber) is filing patent applications on JQ1 derivatives…”
One thing for sure. Love him or hate him, I’m just glad that Dr. Bradner is out there raising awareness for cancer research. Keep us the great work, doc!
Feel good and keep smiling! Pat